Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | TKT | P29401 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21942000 | 0.87 | PIK3CA (0.32) | KDM4EALDH1A1HPGDADRA1AHSD17B10 | |
| SCHEMBL23615487 | 0.80 | FGFR1 (0.32) | KDM4EALDH1A1HPGDADRA1AHSD17B10 | |
| SCHEMBL23615469 | 0.73 | KDM4E (0.34) | KDM4EALDH1A1HPGDADRA1AHSD17B10 | |
| SCHEMBL338669 | 0.71 | AHCY (0.34) | TKT | |
| SCHEMBL338668 | 0.71 | AHCY (0.34) | TKT | |
| SCHEMBL339335 | 0.69 | ADORA2B (0.41) | — | |
| SCHEMBL12809034 | 0.68 | KDM4E (0.46) | KDM4EALDH1A1HPGDADRA1AHSD17B10 | |
| SCHEMBL6974701 | 0.68 | TLR7 (0.41) | TKT | |
| SCHEMBL14725022 | 0.67 | KDM4E (0.31) | KDM4EALDH1A1HPGDADRA1AHSD17B10 | |
| SCHEMBL6983722 | 0.67 | KDM4E (0.31) | KDM4EALDH1A1HPGDADRA1AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10183954-B2 | Oxathiolane carboxylic acids and derivatives for the treatment and prophylaxis of virus infection | HOFFMANN-LA ROCHE INC. (US) | 2019-01-22 | — | — | US | disclosed |
| US-20180065991-A1 | NOVEL OXATHIOLANE CARBOXYLIC ACIDS AND DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2018-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180065991-A1 | NOVEL OXATHIOLANE CARBOXYLIC ACIDS AND DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF VIRUS INFECTION | CXCR1, CCR1, SLC7A1 | KDM4E 4135/4885ALDH1A1 23/4885HPGD 1507/4885 |
| US-10183954-B2 | Oxathiolane carboxylic acids and derivatives for the treatment and prophylaxis of virus infection | CXCR1, CCR1, HAVCR2 | KDM4E 3878/4885ALDH1A1 16/4885HPGD 1559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.